INMB heads into its May 7 earnings with one of the most aggressive short positions in the biotech universe — and a stock price that has quietly been rallying against it.
Short sellers have dug in with real conviction. SI % of free float is running near 15%, a level that ranks in the 4th percentile of all stocks on the ORTEX universe — meaning almost no other name carries a heavier short load relative to its float. That position has grown roughly 6% over the past month as the stock recovered, and the ORTEX short score of 78.2 confirms the crowded-side pressure. Borrow availability is moderate at around 71% of short interest, and cost to borrow has eased to 3.3% from over 6% in mid-April — meaning the borrow market has loosened as availability expanded, reducing the acute squeeze threat even as the short position grew.
Options traders tell a very different story. Bullish sentiment dominates the options market heading into the print: the put/call ratio is a near-record-low 0.10, well below the 20-day average of 0.21, and just off the 52-week floor of 0.09. That PCR is nearly 0.8 standard deviations below the mean — a distinct lean toward calls rather than protection. The stock itself has reinforced the bullish case, climbing 27% over the past month and 10% on the week to close at $1.54. Bulls and bears are not subtly diverging here — they are pointing in opposite directions.
The analyst picture carries real uncertainty. The most recent formal action was a March 2026 upgrade to Buy with a $9 target from Lucid Capital Markets, which is the primary driver of the current three-buy consensus and a $7 mean target. That $7 target implies substantial upside from $1.54 — but note that targets from non-bellwether firms in small biotech can reflect different assumptions than larger-coverage names. Older ratings from July 2025 included a downgrade to Sector Underperform from Scotiabank with a $0.60 target and a Neutral drop from BTIG — those voices are no longer in the formal count but represent the bear thesis: a pre-revenue clinical-stage company at micro-cap scale where cash runway and trial progress are the only metrics that matter. The forward EPS improvement factor score ranks in the 90th percentile, suggesting estimates have been moving higher, though the company remains deeply loss-making.
The earnings release is less a test of financial performance than a clinical-stage checkpoint: investors need to understand where INmune's pipeline stands, what the cash position looks like, and whether the recent price recovery has any fundamental support to match the call-heavy options positioning sitting on top of a historically short float.
See the live data behind this article on ORTEX.
Open INMB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
